US 11,865,111 B2
Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD)
Jonathan A. Bohmann, San Antonio, TX (US); Nadean M. Gutierrez, Devine, TX (US); Joseph A. McDonough, Helotes, TX (US); Robert Francis Campbell, Edgemere, MD (US); Michael Gordon Joyce, Silver Spring, MD (US); Rekha Panchal, Fort Detrick, MD (US); Rajeshwer Sankhala, Bethesda, MD (US); and Allen Duplantier, Stafford, VA (US)
Assigned to Southwest Research Institute, San Antonio, TX (US); The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US); and The Government of the United States, as Represented by the Secretary of the Army, Fort Detrick, MD (US)
Filed by Southwest Research Institute, San Antonio, TX (US); The Government of The United States, as represented by The Secretary of the Army, Fort Detrick, MD (US); and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (US)
Filed on Aug. 11, 2022, as Appl. No. 17/819,178.
Claims priority of provisional application 63/260,342, filed on Aug. 17, 2021.
Prior Publication US 2023/0074535 A1, Mar. 9, 2023
Int. Cl. A61P 31/02 (2006.01); A61K 31/4184 (2006.01); A61K 31/445 (2006.01); A61K 31/551 (2006.01); A61K 31/4468 (2006.01); C07D 295/112 (2006.01); C07D 295/096 (2006.01); C07D 409/04 (2006.01); C07D 223/04 (2006.01)
CPC A61K 31/445 (2013.01) 6 Claims
 
1. A method for treatment of SARS-COV-1, SARS-CoV-2 (Covid-19) and MERS-CoV, and variants within each, in a mammalian subject in need thereof, comprising administering to the subject an effective amount of the following benzimidazole compounds:

OG Complex Work Unit Chemistry
wherein, X can be —CH2— or C═O, and R can be —OCH3 or —NHCH3, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.